Study design and participants
NSCLC, Cancer
DISEASE PROGRESSION, DISEASE, NSCLC, CANCER
This was a single‐center, open‐label, phase II trial conducted at Zhejiang Cancer Hospital, China (Eligible patients were 18–70 years old and had histologically or cytologically confirmed treatment‐experienced advanced NSCLC (AJCC 8th edition), measurable disease, and disease progression after at least two treatment regimens that included one platinum‐containing chemotherapy and one EGFR TKI. Patients with 